BDBM802058 (2S,4R)-1-((S)-3-cyclopropyl- 7,7-dimethyl-7,8-dihydro- 4H,6H[1,2,3]triazolo[5,1-c] [1,4]oxazepine-8-carbonyl)-4- hydroxy-N-((S)-1-(4-(4-meth- ylthiazol-5-yl)phenyl)ethyl)- pyrrolidine-2-carboxamide::US20260108613, Compound A2

SMILES Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]2n3nnc(C4CC4)c3COCC2(C)C)cc1

InChI Key

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 802058   

Targetvon Hippel-Lindau disease tumor suppressor(Human)
University of Michigan

US Patent
LigandChemical structure of BindingDB Monomer ID 802058BDBM802058((2S,4R)-1-((S)-3-cyclopropyl- 7,7-dimethyl-7,8-dih...)
Affinity DataIC50: 7nMAssay Description:JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
9/2/2026
Entry Details
US Patent